Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences

_{//health-fitness.news-articles.net/content/2012/ .. sentations-at-upcoming-investor-conferences.html}
^{Published in Health and Fitness on Monday, May 7th 2012 at 13:31 GMT by Market Wire}  

Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences -- RICHMOND, Calif., May 7, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about SGMO

RICHMOND, Calif., May 7, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: [ SGMO ]) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at the following conferences:

• The 11th Annual JMP Securities Research Conference in San Francisco.  Presentation at 3:00 pm PT (6:00 pm ET), on Monday, May 14, 2012.
• The Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas, NV. Presentation at 2:20 pm PT (5:20 pm ET) on Wednesday, May 16, 2012.

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section [ http://investor.sangamo.com/index.cfm ] under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. It has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS.    Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at [ www.sangamo.com ]

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
[ http://www.sangamo.com ]